Search

Shashikanth S Ponnala

from Tenafly, NJ
Age ~45
Get Report
Also known as:
H Ponnala
Related to:
Savitha Ponnala, 33Siddarth Ponnala, 32Malleswari PonnalaMalleswari Ponnala, 44
Connected to:
Vidoot R Ponnala, 41Gopi K Ponnaluru, 45Satish V Ponnaluri, 49Ashok Ponnambalam, 54Nagendraprasad Ponnam, 40Sudheer Ponnamaneni, 55Abhilash Ponnath, 45Alex Ponnath, 57Sunanda Ponnavolu, 64Yina L Ponnefz, 54

Shashikanth Ponnala Phones & Addresses

  • Tenafly, NJ
  • Secaucus, NJ
  • Jersey City, NJ
  • Hoboken, NJ

Resumes

Resumes

Shashikanth Ponnala Photo 1

Postdoctoral Research Fellow At City University Of New York

View page
Position:
Pst doctoral research scientist at City University of New York
Location:
Greater New York City Area
Industry:
Research
Work:
City University of New York - Manhattan, New York since Nov 2010
Pst doctoral research scientist
Stevens institute of technology, Hoboken, NJ Feb 2010 - Oct 2010
Postdoctoral research fellow
GVK Biosciences - Nacharam, Hyderabad Aug 2006 - Feb 2010
Scientist
Education:
Central drug research institute 2003 - 2006
Ph.D, Oganic chemistry
Skills:
Organic Synthesis
Shashikanth Ponnala Photo 2

Post Doctoral Research Fellow At Stevens Institute Of Technology

View page
Position:
Post Doctoral Research Fellow at Stevens Institute of Technology
Location:
Greater New York City Area
Industry:
Higher Education
Work:
Stevens Institute of Technology
Post Doctoral Research Fellow

Publications

Us Patents

18F-Labeled Triazole Containing Psma Inhibitors

View page
US Patent:
20220194904, Jun 23, 2022
Filed:
Jul 30, 2021
Appl. No.:
17/390284
Inventors:
- Ithaca NY, US
Jasmes M. Kelly - New York NY, US
Shashikanth Ponnala - New York NY, US
Assignee:
Cornell University - Ithaca NY
International Classification:
C07D 249/06
C07C 275/16
A61B 6/03
A61K 9/00
A61K 51/04
C07C 275/24
Abstract:
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula Ior a pharmaceutically acceptable salt thereof, wherein one of R, R, and Risand of Formula IVor a pharmaceutically acceptable salt thereof.

Trifunctional Constructs With Tunablepharmacokinetics Useful In Imaging And Anti-Tumor Therapies

View page
US Patent:
20210128757, May 6, 2021
Filed:
Apr 5, 2018
Appl. No.:
16/500380
Inventors:
- Ithaca NY, US
James M. Kelly - New York NY, US
Shashikanth Ponnala - New York NY, US
Assignee:
CORNELL UNIVERSITY - Ithaca NY
International Classification:
A61K 51/06
A61K 51/04
C07B 59/00
A61P 35/04
A61K 9/00
Abstract:
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.

Trifunctional Constructs With Tunable Pharmacokinetics Useful In Imaging And Anti-Tumor Therapies

View page
US Patent:
20210121584, Apr 29, 2021
Filed:
Dec 23, 2020
Appl. No.:
17/132552
Inventors:
- Ithaca NY, US
James M. Kelly - New York NY, US
Shashikanth Ponnala - New York NY, US
Assignee:
Cornell University - Ithaca NY
International Classification:
A61K 51/04
A61P 35/00
Abstract:
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Trifunctional Constructs With Tunable Pharmacokinetics Useful In Imaging And Anti-Tumor Therapies

View page
US Patent:
20200405888, Dec 31, 2020
Filed:
Sep 9, 2020
Appl. No.:
17/016189
Inventors:
- Ithaca NY, US
James M. Kelly - New York NY, US
Shashikanth Ponnala - New York NY, US
Assignee:
Cornell University - Ithaca NY
International Classification:
A61K 51/04
A61P 35/00
Abstract:
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Compositions For Therapeutics, Targeted Pet Imaging And Methods Of Their Use

View page
US Patent:
20190298864, Oct 3, 2019
Filed:
Sep 9, 2016
Appl. No.:
15/759154
Inventors:
- New York NY, US
Lynn Francesconi - Bridgewater NJ, US
Shashikanth Ponnala - Secaucus NJ, US
Assignee:
Memorial Sloan Kettering Cancer Center - New York NY
Research Foundation of the City University of New York - New York NY
International Classification:
A61K 51/04
A61K 51/10
A61K 9/00
Abstract:
Described herein is a chelator for radiolabels (e.g., Zr) for targeted PET imaging that is an alternative to DFO. In certain embodiments, the chelator for Zr is the ligand, 3,4,3-(LI-1,2-HOPO) (“HOPO”), which exhibits equal or superior stability compared to DFO in chemical and biological assays across a period of several days in vivo. As shown in FIG. , the HOPO is an octadentate chelator that stabilizes chelation of radiolabels (e.g., Zr). A bifunctional ligand comprising p-SCN-Bn-HOPO is shown in FIG. and FIG. . Such a bifunctional ligand can eliminate (e.g., Zr) loss from the chelate in vivo and reduce uptake in bone and non-target tissue. Therefore, the bifunctional HOPO ligand can facilitate safer and improved PET imaging with radiolabeled antibodies.

Trifunctional Constructs With Tunable Pharmacokinetics Useful In Imaging And Anti-Tumor Therapies

View page
US Patent:
20190015531, Jan 17, 2019
Filed:
Sep 18, 2018
Appl. No.:
16/134789
Inventors:
- Ithaca NY, US
James M. Kelly - New York NY, US
Shashikanth Ponnala - New York NY, US
International Classification:
A61K 51/04
A61P 35/00
Abstract:
The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer.

Selective Inhibitors Of Histone Deacetylase Isoform 6 And Methods Thereof

View page
US Patent:
20150197497, Jul 16, 2015
Filed:
Jun 25, 2012
Appl. No.:
14/129108
Inventors:
Chandima Abeywickrama - Wayne NJ, US
James E. Bradner - Weston MA, US
Shashikanth Ponnala - Jersey City NJ, US
Assignee:
DANA-FARBER CANCER INSTITUTE, INC. - Boston MA
International Classification:
C07D 249/04
C07D 235/08
C07D 235/26
C07D 235/10
Abstract:
The described invention provides histone deacetylase (HDAC) inhibitor compounds with substituted benzimidazole, benzimidazolone and benzotriazole heterocycles showing selective inhibition of histone deacetylase isoform HDAC6. The described invention further provides methods of making such compounds and methods of inhibiting HDAC, treating HDAC-associated diseases, including cell proliferative disorders, such as cancer, autoimmune or inflammatory diseases and neurodegenerative diseases.
Control profile
Shashikanth S Ponnala from Tenafly, NJ, age ~45 Get Report